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Goal: The goal of this lesson is to 
discuss current medical management of 
dyslipidemias, including available agents 
and goals of therapy, as well as potential 
future treatment strategies based on 
recently published literature. 
 
Objectives: At the conclusion of this 
lesson, successful participants should be 
able to: 
1. Define patient-specific lipid goals 
based on risk factors. 
2. Describe agents used in the treatment 
of dyslipidemias, including HMG-
CoA reductase inhibitors, bile acid 
sequestrants, cholesterol absorption 
inhibitors, niacin, fibric acids, and 
omega-3 fatty acids. 
3. Identify the role of each class of 
agents in lipid management, as 
recommended by current guidelines 
and practice. 
4. Discuss the impact of recently 
published literature on current lipid 
management strategies.  
 
INTRODUCTION 
 
Current guidelines mandate strict 
low‐density lipoprotein (LDL) control in 
patients with coronary heart disease 
(CHD) or those at high risk for 
atherosclerotic disease. LDL cholesterol 
has been established in several clinical 
trials as a predictor of coronary 
atherosclerosis. Further, a reduction in 
LDL by one percent has been shown to 
decrease cardiovascular risk by one 
percent. The breadth of evidence behind 
reduction in LDL and decreased 
cardiovascular risk is the driving force 
behind treating to a target LDL goal.1 
 
In 2004, the Adult Treatment Panel III 
(ATP III) guidelines were updated to 
include an optional LDL treatment goal 
of <70 mg/dL in patients at very high 
risk, particularly those with documented 
coronary heart disease.2  Table 1 
provides the current ATP III risk 
stratification used in clinical practice 
today. Risk factors for increased 
probability of having a CHD event 
include age, gender, family history, 
hypertension, and cigarette smoking. 
These risk factors can be used to assess 
the 10 year risk for cardiovascular 
events. 
 
Although targeting lower LDL is the 
primary goal of therapy, consideration 
must be given to other lipoproteins. 
Triglyceride (TG), very low density 
lipoprotein (VLDL), and high density 
lipoprotein (HDL) goals have all been 
evaluated in clinical trials.3-4  In response 
to new literature, the American Heart 
Association (AHA) published a 
statement on triglycerides and 
cardiovascular disease in 2011.3  
Additionally, the lipid research clinic 
cohort demonstrated a strong correlation 
between non‐HDL cholesterol and 
cardiovascular mortality, thus making 
non‐ HDL targets appropriate for 
consideration in some patients.4  Lastly, 
HDL has long been considered a 
protective lipoprotein, though no 
guidelines give specific 
recommendations for goals of therapy. 
 
The purpose of this review is to discuss 
agents used to treat dyslipidemias 
(shown in Table 2), describe current 
goals of therapy, and discuss the impact 
of recently published literature on current 
lipid management strategies. 
 
AGENTS 
 
HMG‐CoA Reductase Inhibitors 
 
HMG‐CoA reductase inhibitors, or 
“statins,” are considered the most 
effective LDL‐reducing agents currently 
available.1  These agents inhibit the 
conversion of HMG‐CoA to mevalonate 
by the enzyme HMG‐CoA reductase, the 
rate liming step in cholesterol synthesis.5-
11  In addition to decreasing LDL 
cholesterol, these agents also lead to 
increases in HDL cholesterol and 
decreases in triglycerides. 
 
While statins are generally 
well‐tolerated, they may lead to skeletal 
muscle effects, such as myopathy and/or 
rhabdomyolysis.  Patients may 
commonly report muscle aches, soreness, 
and weakness. Myopathies are more 
common in elderly patients and in 
patients taking additional 
myopathy‐causing agents. Management 
of a statin induced myopathy can include 
a drug holiday, dose decrease, or 
switching to an alternate statin.12 
Statin‐induced myopathies may also lead 
to an elevation in creatinine kinase, 
which is most concerning when reaching 
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greater than ten times the upper limit of 
normal. These patients are at risk for 
developing rhabdomyolysis and acute 
renal failure if statin therapy is not 
reduced or discontinued. 
 
Statins may also lead to increased hepatic 
transaminases. This elevation in liver 
function tests (LFTs) is typically 
dose‐dependent, and a decline in LFTs is 
usually observed after a statin dose 
reduction. Those experiencing persistent 
transaminase elevations at greater than 
three times the upper limit of normal 
should discontinue statin therapy.5-11  
Previously, the U. S. Food and Drug 
Administration (FDA) recommended that 
patients initiating statin therapy have 
LFTs checked at baseline, after 12 weeks 
of therapy, and then periodically 
thereafter. Recently, the labeling for 
these medications was updated by the 
FDA to include new recommendations 
for LFT monitoring.  Current 
recommendations state that LFTs should 
be checked prior to initiation and then as 
needed based on clinical suspicion of 
liver dysfunction.13 
 
Contraindications to statin use include 
active liver disease, pregnancy or 
breastfeeding, and sensitivity to statins. 
Statin use may also be problematic in 
terms of potential drug interactions, as 
they are metabolized via the cytochrome 
P450 (CYP450) isoenzymes. Some of 
the statins are metabolized via the 
CYP450 3A4 isoenzyme (see Table 3); 
therefore, drugs that are strong inhibitors 
of this isoenzyme should be avoided in 
patients receiving a statin. Pravastatin 
and pitavastatin may be beneficial in this 
regard, as they have been shown to have 
minimal effects on the CYP450 
isoenzymes. 
 
Statins are typically dosed once daily. 
Because of increased LDL‐lowering 
effects during the night, statins should 
generally be administered in the 
evening. Statins with relatively longer 
half-lives (atorvastatin, pitavastatin, 
pravastatin, rosuvastatin), however, can 
be administered at any time of the day. 
 
 
 
 
Bile Acid Sequestrants 
 
Bile acid sequestrants work by binding to 
bile acids in the gastrointestinal tract, 
which leads to decreased enterohepatic 
recycling and subsequent increased bile 
acid excretion in the feces.14-16  Because 
cholesterol is a major prescursor of bile 
acids, removal in the feces leads to 
increased removal of cholesterol from the 
serum to form new bile acids. 
 
Due to the lack of absorption in the GI 
tract, bile acid sequestrants have minimal 
systemic adverse effects. They are 
capable, however, of causing severe 
gastrointestinal side effects, the most 
common being constipation. Bile acid 
sequestrants may also lead to nausea, 
vomiting, diarrhea, and abdominal pain 
or discomfort. These effects are 
dose‐dependent and are seen less often 
with low to moderate doses. 
 
Bile acid sequestrants may also lead to 
increased triglycerides by stimulating 
triglyceride production and promoting 
triglyceride‐rich VLDL secretion. As a 
result, bile acid sequestrants are 
contraindicated in patients with serum 
triglycerides greater than 500 mg/dL and 
in patients with a history of pancreatitis 
caused by hypertriglyceridemia. 
 
Bile acid sequestrants may also have 
significant drug‐drug interactions due to 
their role in altering the absorption of 
other medications. To avoid this 
potential interaction, other medications 
should be taken at least one hour before 
or at least four hours after administration 
of a bile acid sequestrant. Colesevelam 
may not alter absorption of other 
medications as much as the other agents 
in this class and can be administered 
concomitantly with other medications. 
 
Bile acid sequestrants are dosed once or 
twice daily and are administered with 
meals. Cholestyramine and colesevelam 
are commercially available in powder 
form. These agents should be mixed 
with water or other liquid, including 
juices and soups. Colestipol and 
colesevelam are available in tablet forms. 
Current guidelines highlight the additive 
LDL‐lowering effects of bile acid 
sequestrants when combined with other 
agents such as statins. 
 
Cholesterol Absorption Inhibitors 
 
Ezetimibe is the only currently available 
agent in the cholesterol absorption 
inhibitor class.  It works at the brush 
border of the small intestine to inhibit 
cholesterol absorption in the 
gastrointestinal tract.17  This unique 
mechanism of action allows ezetimibe to 
be added to other therapies for LDL 
reduction. 
 
Ezetimibe has been associated with an 
increased incidence of myopathies and 
rhabdomyolysis. While the majority of 
these reported cases have been in 
patients also taking a statin, myopathies 
have occurred in patients receiving 
ezetimibe monotherapy. If patients 
present with myopathy, including 
creatinine kinase greater than 10 times 
the upper limit of normal, ezetimibe 
should be discontinued. Ezetimibe may 
also cause increased hepatic 
transaminases, especially when 
co‐administered with a statin. If patients 
present with LFTs greater than 3 times 
the upper limit of normal, ezetimibe 
should be discontinued.  
 
Ezetimibe is contraindicated in patients 
with active liver disease, pregnancy and 
breastfeeding, and hypersensitivity to 
any part of the formulation. This agent 
does not contribute to significant 
drug‐drug interactions. 
 
Ezetimibe is typically dosed once daily 
and can be taken without regard to 
meals. 
 
Niacin 
 
Niacin, or nicotinic acid, works by 
inhibiting free fatty acid release from 
adipose tissue, increasing lipoprotein 
lipase activity, and increasing 
triglyceride removal from plasma by 
chylomicrons.1,18  Niacin is beneficial in 
reducing LDL cholesterol and 
triglycerides while also increasing HDL 
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cholesterol. 
Niacin therapy can be difficult for 
patients to tolerate, with the most 
common side effect being flushing. 
While flushing typically subsides with 
continued use, measures can be taken to 
reduce the incidence. Pre‐treating with 
aspirin prior to niacin administration, 
administering niacin with a meal, and 
taking niacin in the evening are all 
beneficial recommendations to reduce 
the incidence of flushing. Additionally, 
the branded product Niaspan® is an 
extended‐release formulation that has 
demonstrated less flushing than 
immediate‐release niacin.19 
 
Other adverse effects of niacin include 
gastrointestinal effects such as nausea, 
vomiting, diarrhea, and dyspepsia. 
Hepatotoxicity is a severe adverse 
reaction associated with niacin use; this 
risk appears to be increased in patients 
using sustained or extended‐release 
niacin formulations. Niacin can also 
lead to glucose dysregulation and 
hyperuricemia. 
 
Niacin is typically dosed once or twice 
daily. It is commercially available as 
both over‐the‐counter and 
prescription‐only formulations. When 
switching from an immediate‐release 
form of niacin to an extended‐ release 
product, equivalent doses should not be 
given; extended‐release niacin should be 
restarted at a low dose and titrated to 
response. 
 
Fibric Acid Derivatives 
 
Fibric acid derivatives, or “fibrates,” 
work as agonists at the peroxisome 
proliferator activated receptor α 
(PPARα), leading to overall increased 
lipolysis and removal of triglycerides 
from the plasma. Hence, these agents 
are most beneficial in reducing 
triglycerides.20-21 
 
Fibrates are generally well tolerated by 
patients.1  The most common adverse 
effects are gastrointestinal in nature 
(nausea, constipation, etc.). These 
agents have been linked to an increased 
risk of gallstone development. Fibrates 
may also lead to an increased serum 
creatinine, so renal function should be 
monitored in patients at risk for renal 
impairment. Additional caution should 
be used in patients receiving nephrotoxic 
agents. 
 
Patients taking fibrates should be 
regularly monitored for the development 
of myopathies (especially when using a 
concomitant statin agent) and for 
increases in LFTs. 
 
Fibrates should be avoided in patients 
with pre‐existing renal, hepatic, or 
gallbladder dysfunction. Fibrates may 
have significant drug‐drug interactions 
due to a strong affinity to albumin. 
Fibrates bind to albumin and may lead to 
displacement of other albumin‐bound 
drugs, such as warfarin. 
 
Fibrates are typically dosed once daily. 
The majority of commercially available 
agents can be administered without 
regard to meals; however, some 
formulations must be taken with food. 
 
Omega‐3 Fatty Acids 
 
Omega‐3 fatty acids (EPA and DHA) 
are primarily used to decrease 
triglycerides.1 These agents have several 
proposed mechanisms of action 
including increased hepatic oxidation, 
decreased hepatic synthesis of 
triglycerides, and increased lipoprotein 
lipase activity in the plasma. 
 
The most common side effects 
associated with omega‐3 fatty acids 
include belching, dyspepsia, and taste 
disturbances. These agents may also 
lead to increased LFTs; these should be 
routinely monitored, especially in 
patients with pre‐existing hepatic 
dysfunction. Omega‐3 fatty acids may 
also increase LDL cholesterol. 
 
Omega‐3 fatty acids should be used with 
caution in patients with an allergy to fish 
or shellfish, as they are derived from fish 
sources. 
 
Few drug interactions exist with 
omega‐3 fatty acids. These agents may, 
however, lead to prolonged bleeding 
time. Use of omega‐3 fatty acids with 
other anticoagulant or antiplatelet agents 
should be monitored closely. 
 
Omega‐3 fatty acids are commercially 
available as both over‐the‐counter fish oil 
and a prescription‐only formulation 
(Lovaza®).22  Unlike Lovaza®, the 
quality and efficacy of over-the-counter 
products are not regulated by the FDA 
and may provide inconsistent reductions 
in triglycerides.23 Lovaza® should be 
dosed one to two times per day and can 
be administered without regard to food. 
 
LIPID GOALS 
 
Released in 2001, the Third Report of the 
National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment 
Panel III) identifies serum LDL 
cholesterol as a major cause of coronary 
heart disease (CHD) and thus the primary 
target for lipid‐ lowering therapy.1   LDL 
goals are based on number of CHD risk 
factors and calculation of 10‐year risk 
using the Framingham risk score. 
Current LDL goals and treatment 
recommendations are found in Table 1. 
 
One exception to LDL‐lowering as the 
primary therapeutic goal exists. When a 
patient presents with triglycerides greater 
than 500 mg/dL, lowering triglycerides 
to less than 500 mg/dL becomes a 
priority, in effort to reduce the risk of 
pancreatitis secondary to 
hypertriglyceridemia.1   Once 
triglycerides have been decreased to less 
than 500 mg/dL, the focus returns to 
LDL‐lowering.  After the LDL goal is 
achieved, ATP III recommends further 
goals depending on other lipid levels. 
For patients with triglycerides ≥ 200 
mg/dL, lowering non‐HDL cholesterol to 
a target 30 mg/dL higher than the LDL 
goal should be the secondary focus. 
When triglycerides are normal or 
borderline high (< 200 mg/dL) and HDL 
is low (< 40 mg/dL), the addition of a 
medication to increase HDL can be 
considered, particularly in patients with 
significant CHD risk.  The currently 
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accepted classifications of LDL, 
triglyceride, and HDL levels are listed in 
Table 4. 
 
While the ATP III recommendations 
remain the gold‐standard for cholesterol 
management, a growing body of 
evidence and recommendations exist 
supporting the consideration of 
triglycerides, non‐HDL, and HDL when 
initiating and titrating medications for 
lipid management. 
 
Triglycerides 
 
Whether plasma triglyceride 
concentrations represent an independent 
risk factor for CHD has been a subject of 
research and debate for decades, and the 
evidence remains conflicting.3  Data 
from the Framingham Heart Study 
support hypertriglyceridemia as an 
independent risk factor in women 50 to 
69 years of age.24  Similarly, a 
relationship between triglycerides and 
coronary artery disease (CAD) in 
patients with Type II diabetes mellitus 
was established by the Paris Prospective 
Study.25  In other prospective trials, the 
association between triglycerides and 
cardiovascular risk has been dampened 
when other established risk factors were 
taken into account.26  This effect was 
demonstrated in a meta‐analysis of 
seventeen studies completed between 
1959 and 1991.27  When considered 
independently, patients with elevated 
triglycerides were found to have a 
significantly increased relative risk of 
cardiovascular events (RR 1.32 for 
males, 1.76 for females).  When adjusted 
for other risk factors, the values 
maintained statistical significance but 
were decreased to 1.14 for males and 
1.37 for females. 
 
A more convincing evidence base 
supports hypertriglyceridemia as a CAD 
risk factor when found in combination 
with other risk factors. The Helsinki 
Heart Study was a randomized, 
double‐blind, placebo‐controlled trial 
originally designed to study the effects of 
gemfibrozil on the incidence of CHD in 
men aged 40‐55 years with dyslipidemia 
at baseline.28  A post hoc analysis was 
performed on the data collected during 
the 5‐year study period to determine the 
combined effect of baseline triglyceride, 
LDL, and HDL concentrations on cardiac 
outcomes. Results of this secondary 
analysis suggest that middle‐aged men 
with elevated plasma triglycerides along 
with low HDL cholesterol and high LDL 
cholesterol are at increased CHD risk and 
may significantly benefit from long‐term 
lipid‐lowering therapy with gemfibrozil. 
 
In 2011, the American Heart Association 
(AHA) published a statement on 
triglycerides and cardiovascular disease.3   
After reviewing the role of triglycerides 
in lipid metabolism and atherogenesis, as 
well as the available evidence related to 
potential complications of 
hypertriglyceridemia, the AHA suggests 
an optimal fasting triglyceride level of 
less than 100 mg/dL (less than 200 
mg/dL non‐fasting). Intensive 
therapeutic lifestyle modifications are 
strongly encouraged and may be 
effective in achieving triglyceride goals. 
The combination of weight reduction, 
limitation of dietary fat, and an increase 
in physical activity has the potential to 
achieve a 50% reduction in triglycerides. 
 
Non‐HDL 
 
The role of apolipoprotein B (apoB), and 
thus apoB‐containing lipoproteins, in the 
process of atherogenesis has been 
increasingly highlighted in the last few 
years.3  Non‐HDL cholesterol represents 
all apolipoprotein B containing 
lipoproteins, including LDL and VLDL. 
Some evidence exists suggesting a 
stronger link between CHD risk and 
non‐HDL than with LDL. 
 
A recent meta‐analysis published by 
Boekholdt and colleagues looked at the 
relationship between various lipid 
markers and the risk of cardiovascular 
events in patients receiving statin 
therapy.29  Criteria for inclusion in the 
meta‐analysis consisted of randomization 
of at least one study group to statin 
therapy; measurement of total 
cholesterol, LDL, HDL, triglycerides, 
and apolipoproteins at baseline and at 
some point during therapy; mean follow 
up of at least 2 years; and at least 1000 
participants. The authors identified eight 
randomized controlled trials meeting 
these criteria and acquired individual 
patient data from each. The primary 
outcome was defined as time to first 
major cardiovascular event, which 
included a composite of fatal and 
nonfatal events. 
 
A statistically significant relationship 
was found between all studied lipid 
markers and cardiovascular risk. 
Interestingly, patients treated with statins 
who achieved their non‐HDL goal (130 
mg/dL) but not their LDL goal (100 
mg/dL) had a similar risk of 
cardiovascular event as those reaching 
both targets, but patients who achieved 
their LDL goal but not their non‐HDL 
goal were at increased risk. Thus, the 
authors concluded that non‐HDL 
cholesterol was more strongly associated 
with cardiovascular risk than LDL.  
Based on these and previous results, 
non‐HDL may have clinical utility as a 
target for initiating and titrating statin 
therapy. 
 
HDL 
 
HDL has long been considered a 
protective lipoprotein, with a strong 
inverse relationship identified between 
HDL levels and CHD. Based on results 
from the Framingham Heart Study, ATP 
III recognizes an HDL of ≥ 60 mg/dL as 
a “negative” risk factor for CHD.1 
However, no current guidelines outline 
specific recommendations for target 
HDL levels. Within the last two years, 
new literature has become available 
regarding the effectiveness of targeting 
HDL goals in patients who have been 
treated to their LDL goals. 
 
The AIM‐HIGH investigators published 
the results of a study evaluating the 
effect on cardiovascular events when 
extended‐release niacin was added to 
aggressive statin therapy.30  The study 
was, in part, a response to data from a 
post hoc analysis of the Treating to New 
Targets (TNT) trial which showed fewer 
cardiovascular events in patients with 
higher HDL levels, compared to those 
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with lower HDL levels, when patients 
were treated to an LDL goal of less than 
70 mg/dL.31  Patients included in the 
AIM‐HIGH study had established 
cardiovascular disease along with low 
HDL and high triglycerides at baseline. 
All subjects received simvastatin with or 
without ezetimibe to treat to an LDL of 
40 to 80 mg/dL, while the study group 
also received niacin at a dose of 1500 to 
2000 mg per day.  Of note, 
approximately 94% of patients were 
taking a statin prior to enrollment in the 
study, and the median LDL at baseline 
was 71 mg/dL for this group.  
 
While the addition of niacin was 
associated with increases in HDL and 
decreases in triglycerides, no significant 
difference was seen in the primary 
cardiovascular endpoint (death from 
CHD, nonfatal myocardial infarction, 
ischemic stroke, hospitalization for acute 
coronary syndrome, or symptom‐ driven 
coronary or cerebral revascularization).  
Thus, the authors concluded that 
increasing HDL and decreasing 
triglycerides adds no clinical benefit to 
intensive LDL control in patients with 
pre‐existing cardiovascular disease. 
 
Much discussion was sparked in the 
medical community with the release of 
the AIM‐HIGH results. Criticism of the 
study included its inadequate statistical 
power, the small absolute difference in 
HDL between treatment and placebo 
groups, and the continued titration of 
other LDL‐lowering therapies 
(simvastatin and ezetimibe) throughout 
the study.32  Additionally, the 
discrepancy between results of the 
AIM‐HIGH trial and the TNT trial may 
be at least partially explained by the 
observation that patients in the 
AIM‐HIGH trial achieved a mean HDL 
of 44 mg/dL, while subjects in the 
highest HDL quintile in the TNT trial 
had a mean HDL of 61.5 mg/dL at 
baseline.30-31 
 
Based on the results of AIM‐HIGH, it is 
unclear whether raising HDL, and in 
particular the use of niacin to accomplish 
this, is a beneficial target in clinical 
practice. The HPS2‐THRIVE study is 
currently being conducted to further 
evaluate the effects of increasing HDL 
with a niacin‐based regimen on 
cardiovascular outcomes.33  It is hoped 
that, with a larger study population and 
less controversial methodology, the 
THRIVE study will produce results that 
clarify the role of niacin and HDL in 
lipid management. 
 
 
CONCLUSIONS 
 
Interest in cholesterol management is 
ever increasing, as management within 
recommended goals has been linked to 
various health benefits, including 
decreased cardiovascular disease. Many 
treatment options currently exist to help 
manage patients with dyslipidemia 
according to ATP III guidelines. While 
LDL‐lowering remains the primary goal 
of therapy at this time, a building body of 
evidence supports consideration of other 
lipid goals to minimize cardiovascular 
risk. As further research is completed 
and practice guidelines are updated, an 
increased emphasis may be placed on 
lowering triglycerides and non‐HDL 
cholesterol. 
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TABLE 1: 
 
Risk Category Treatment Goal Recommended Treatment 
Strategy 
High Risk 
CHD or CHD risk 
equivalents CHD Risk 
Equivalents: Framingham 
>20% 
Diabetes mellitus  
LDL < 100mg/dL 
Optional LDL goal <70mg/dL
LDL > 100mg/dL 
Initiate lifestyle modifications 
 
LDL > 130mg/dL 
Initiate drug therapy 
Moderate Risk 
2+ risk factors 
AND 
Framingham 10% to 20% 
LDL < 130mg/dL LDL > 130mg/dL 
Initiate lifestyle modifications 
 
LDL > 160mg/dL 
Initiate drug therapy 
Low Risk 
0 to 1 risk factor 
Framingham < 10% 
LDL < 160mg/dL LDL > 160mg/dL 
Initiate lifestyle modifications 
 
LDL > 190mg/dL 
Initiate drug therapy 
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TABLE 2: 
 
Agents Used in the Treatment of Dyslipidemia 
Agent Brand Name(s) Total Daily 
Dose 
Range 
Effect on 
LDL 
Effect on 
TG 
Effect on 
HDL 
Approximate Cost 
for 30‐Day Supply 
HMG‐CoA Reductase Inhibitors 
Atorvastatin Lipitor ® 10 – 80 mg ↓ 39 – 60% ↓ 19 –37% ↑ 5 – 9% +++* 
Fluvastatin Lescol ®; 
Lescol XL 
20 – 80 mg ↓ 22 – 36% ↓12 –25% ↑ 3 – 11% +++ 
Lovastatin Mevacor ®; 
Altoprev ® 
20 – 60 mg ↓ 21 – 32% ↑9 – ↓10% ↑ 2 – 8% +* 
Pitavastatin Livalo ® 1 – 4 mg ↓ 32 – 43% ↓ 15 –18% ↑ 5 – 8% +++ 
Pravastatin Pravachol ® 10 – 80 mg ↓ 22 – 37% ↓ 11 –24% ↑ 2 – 12% +* 
Rosuvastatin Crestor ® 5 – 40 mg ↓ 45 – 63% ↓ 10 –35% ↑ 8 – 14% ++++ 
Simvastatin Zocor ® 5 – 80 mg ↓26 – 47% ↓ 12 –33% ↑ 8 – 16% +* 
Bile Acid Sequestrants 
Cholestyramine Prevalite ®; 
Questran ®; 
Questran Light® 
4 – 24 g ↓10 – 20% ↑ 5% Little effect +++ 
Colesevelam  3.75 g ↓15 – 18% ↑ 9% ↑ 3%  
Colestipol Colestid ® 5 – 30 g ↓10 – 20% ↑ 5% Little effect +* 
Cholesterol Absorption Inhibitors 
Ezetimibe Zetia ® 10 mg ↓18% ↓8% ↑ 1% +++ 
Niacin 
Niacin Niacor®; 
Niaspan®; 
Slo‐Niacin® 
1 – 3 g ↓7 – 16% ↓16 – 
38% 
↑ 14 – 
22% 
+++ 
Fibric Acid Derivatives 
Fenofibrate Antara®; 
Fenoglide®; 
Lipofen®; 
Lofibra®; 
TriCor®; 
Triglide® 
40 – 200 
mg 
↓21% ↓29% ↑ 11% +* 
Gemfibrozil Lopid ® 1200 mg ↓ 10‐15% ↓ 35‐50% ↑ 5‐20% +* 
Omega – 3 Fatty Acids (EPA and DHA) 
Omega‐3‐acid 
ethyl esters 
Lovaza ® 4 g ↑ 45% ↓45% ↑ 9% ++++ 
+ = $1 – 50 
++ = $51 – 100 
+++ = $101 – 150 
++++ = $151 = 200 
* = includes generic drug pricing 
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TABLE 3: 
 
Differences in Statin Metabolism via CYP450 3A4 
CYP3A4 Involvement/ Lipophilic Agents No CYP 3A4 Involvement / Hydrophilic Agents 
Lovastatin Fluvastatin 
Simvastatin Pravastatin 
Atorvastatin Rosuvastatin 
* Pitavastatin is a lipophilic statin that has no CYP 3A4 involvement 
 
 
TABLE 4: 
 
LDL (mg/dL)  
<100 Optimal 
100‐129 Above or near optimal 
130‐159 Borderline high 
160‐189 High 
>190 Very high 
Triglycerides (mg/dL)  
<150 Normal 
150‐199 Borderline high 
200‐499 High 
>500 Very high 
HDL (mg/dL)  
<40 Low 
>60 High 
 
 
 
 
 
 
 
Test name: 2012 Article #8: Lipid Goals - Update on their Status
This test is worth: 10 points
INSTRUCTIONS: This page is intended to help participants REVIEW the quiz questions prior to submitting their
answers online. Please take the quiz online using the link in the MEMBERS section of the website.
Question 1 of 19
Did the article help you achieve EACH of the stated objectives? If not, describe in the comment box at the
end of this section. Refer to the article for the list of learning objectives.
A) Yes
B) No
Question 2 of 19
Quality of the written material/content?
A) Very Good Quality
B) Good Quality
C) Neutral
D) Poor Quality
E) Very Poor Quality
Question 3 of 19
Overall evaluation of this article?
A) Very Good
B) Good
C) Neutral
D) Poor
E) Very Poor
Question 4 of 19
How much time was required to complete this article?
A) 0.5 hours
B) 1.0 hours
C) 1.5 hours
D) 2.0 hours
E) 2.5 hours
Question 5 of 19
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The learning activities (e.g. case studies, quiz) were effective?
A) Strongly Agree
B) Agree
C) Neutral
D) Disagree
E) Strongly Disagree
Question 6 of 19
The information in this article will help assist and reinforce my practice/treatment habits?
A) Strongly Agree
B) Agree
C) Neutral
D) Disagree
E) Strongly Disagree
Question 7 of 19
The author(s) did NOT appear to be promoting a product or company? Please use COMMENT box at end
of evaluation to explain or provide comment.
A) Strongly Agree
B) Agree
C) Neutral
D) Disagree
E) Strongly Disagree
Question 8 of 19
Author(s) communicated material clearly?
A) Strongly Agree
B) Agree
C) Neutral
D) Disagree
E) Strongly Disagree
Question 9 of 19
Comments. Please use this space to provide comments related to any of the above questions.
If NO COMMENT, please write " NONE " in the box below.
Question 10 of 19
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SN is a 48-year-old female with a past medical of asthma, type 2 diabetes mellitus, hypertension, and
migraines. She has no family history of coronary heart disease. She does not have a history of cigarette
smoking. Her most recent HDL = 55 mg/dL. Based on her risk factors, what is SE's LDL goal?
A) < 160 mg/dL
B) < 145 mg/dL
C) < 130 mg/dL
D) < 100 mg/dL
Question 11 of 19
KA is a 52 year old male with no significant past medical history; however, his mother had a myocardial
infarction at the age of 56 years old. He is a non-smoker, and his most recent HDL = 45 mg/dL. What is
his LDL goal?
A) < 160 mg/dL
B) < 130 mg/dL
C) < 100 mg/dL
D) < 70 mg/dL
Question 12 of 19
Which of the following represents an appropriate recommendation regarding timing of liver function test
(LFT) monitoring?
A) Prior to initiating a statin, then only as clinically indicated.
B) Prior to initiating a statin, then every 12 weeks as long as the statin is continued.
C) Prior to initiating a statin, then annually as long as the statin is continued.
D) LFTs do not need to be monitored in patients taking statins.
Question 13 of 19
Which of the following agents results in drug-drug interactions that would warrant separating
administration of other medications (given at least one hour before or two hours after)?
A) Fluvastatin
B) Cholestyramine
C) Gemfibrozil
D) Ezetimibe
Question 14 of 19
What percentage decrease in LDL would be expected with ezetimibe 10 mg by mouth daily?
A) 8%
B) 11%
C) 18%
D) 28%
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Question 15 of 19
All of the following are potential adverse reactions associated with niacin EXCEPT:
A) Hyperuricemia
B) Glucose dysregulation
C) Flushing
D) Gallstone formation
Question 16 of 19
Which of the following is the most appropriate first line agent for a patient with an LDL of 182 mg/dL, HDL
of 46 mg/dL, and triglycerides of 529 mg/dL?
A) Colestipol
B) Ezetimibe
C) Fenofibrate
D) Pitavastatin
Question 17 of 19
Which of the following is NOT true of omega-3 fatty acids?
A) Have favorable effects on LDL, triglycerides, and HDL
B) Available as prescription and over-the-counter formulations
C) May lead to prolonged bleeding time
D) Should not be used in patients with a shellfish allergy
Question 18 of 19
Which of the following is true regarding non-HDL goals?
A) Current guidelines recommend targeting non-HDL goals prior to achieving other cholesterol
goals
B) Non-HDL goals are typically 30 mg/dL lower than the LDL goal.
C) Non-HDL has been suggested to be more strongly related to cardiovascular risk than LDL.
D) All of the above are true.
Question 19 of 19
Which of the following is true regarding HDL goals?
A) Current guidelines recognize HDL ≥ 70 mg/dL as a negative risk factor for CHD.
B) TNT showed fewer cardiovascular events in patients with higher HDL levels, regardless of the
LDL achieved with therapy.
C) AIM-HIGH found that increasing HDL and decreasing triglycerides lead to significant differences
in the primary cardiovascular endpoint.
D) Discrepancies in TNT and AIM-HIGH study conclusions may be attributed to differences in mean
HDL achieved during the course of each study.
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